Amedisys Inc. (Nasdaq: AMED) skilled development of house well being within the fourth quarter of 2024, regardless of the decision of merger-related prices of the hanging acquisition by UnitedHealth Group (NYSE: UNH).

The house well being actions of the corporate reported the online service turnover of $ 377 million for the fourth quarter of 2024, a rise of $ 358.9 million in the identical quarter of the earlier 12 months. For the complete 12 months of 2024, the online service turnover amounted to $ 1.49 billion, a rise of $ 1.4 billion in 2023.

Within the fourth quarter, the online turnover of the corporate rose by $ 27.3 million to achieve $ 598 million, in comparison with $ 570 million in 2023. The corporate didn’t maintain a revenue name, given the hanging acquisition of the corporate.

The prospects for that deal are unsure, because the US Division of Justice (DOJ) Amedisys and UnitedHealth Group Kandsinks to dam the transaction due to inflicting antitrust.

In June 2023, the subsidiary of UnitedHealth Group agreed to amass Amedisys for $ 101 per share in a transaction with a full contract with a price of round $ 3.3 billion. Final summer season the Doj began to research potential antitrust issues with regard to the deal.

The DOJ carried out an identical research and introduced a lawsuit when Optum has taken over the well being care of healthcare. A federal court docket lastly allowed that deal to proceed.

The reasoning behind the lawsuit of the Ministry of Justice towards Optum and Amedisys is advanced, geared toward doable destructive results on competitors, at house -based care employees and payers.

Amedisys provides house well being, hospice and palliative care companies to greater than 465,000 sufferers in 38 states and Washington DC yearly